Furin-cleaved Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Active and Modulates Low Density Lipoprotein Receptor and Serum Cholesterol Levels
Authors:
Open Access
- 1 December 2012
- journal article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 287 (52) , 43482-43491
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Effect of a Monoclonal Antibody to PCSK9 on LDL CholesterolNew England Journal of Medicine, 2012
- Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemiaNature Structural & Molecular Biology, 2007
- The Proprotein Convertase (PC) PCSK9 Is Inactivated by Furin and/or PC5/6AJournal of Biological Chemistry, 2006
- Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart DiseaseNew England Journal of Medicine, 2006
- Novel mutations of thePCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemiaHuman Mutation, 2005
- Hepsin promotes prostate cancer progression and metastasisCancer Cell, 2004
- Tissue Expression, Protease Specificity, and Kunitz Domain Functions of Hepatocyte Growth Factor Activator Inhibitor-1B (HAI-1B), a New Splice Variant of HAI-1Journal of Biological Chemistry, 2003
- Mutations in PCSK9 cause autosomal dominant hypercholesterolemiaNature Genetics, 2003
- The First Epidermal Growth Factor-like Domain of the Low-Density Lipoprotein Receptor Contains a Noncanonical Calcium Binding SiteBiochemistry, 2001
- On the size of the active site in proteases. I. PapainBiochemical and Biophysical Research Communications, 1967